Health and Environment – Pharmaceuticals development

Fraunhofer scientists research pharmaceutical agents for the treatment of diseases such as cancer, allergies, inflammatory and autoimmune conditions, and infections. For the production of pharmaceutical agents used in preclinical and clinical trials, we have at our disposal the most state-of-the-art equipment meeting the specifications of the European Medicines Agency EMEA and the American Food and Drug Administration FDA. Pharmaceutical agents and manufacturing processes are developed in accordance with the rules of the Good Manufacturing Process (GMP).

Gesundheit und Umwelt


AETIONOMY organizes knowledge about dementia to develop new drugs and therapies

The AETIONOMY consortium started a project aiming to develop a new way to classify Alzheimer’s and Parkinson’s disease. The 5-year-project is funded by the Innovative Medicines Initiative (IMI), a joint undertaking between the European Union and the pharmaceutical industry association EFPIA. The new classification will be generated using data derived from a wide range of new biological approaches and will be based on the underlying causes of the disease. Currently, Alzheimer’s disease and Parkinson’s disease are classified by their symptoms and severity but it is clear that this does not represent the many different causes of these diseases. It has been widely recognised that within these broad disease groups there are sub-groups where the different causes result in the symptoms of memory loss or movement disorder.



Launch of the PHAGO project to explore a new approach for patients suffering from Alzheimer’s disease

On 1st November 2016 the Innovative Medicines Initiative (IMI) together with an association of industrial partners came together to support PHAGO, an innovative research project devoted to the development of immunomodulatory therapies for Alzheimer’s disease (AD).



Information integration and artificial intelligence for better diagnosis and therapy decisions

Research alliance between Fraunhofer MEVIS and Siemens Healthineers develops decision support systems for physicians based on deep machine learning.




More efficient vaccine production

Using electrons to inactivate viruses

Viral inactivation by means of electron irradiation.
© Fraunhofer IZI

Viral inactivation by means of electron irradiation.

Many vaccines contain viruses that are inactivated to prevent them from harming recipients. This is generally achieved by adding chemicals. Fraunhofer scientists are taking a different approach, using low-energy-electrons to irradiate the pathogens. The advantages of this new method are that it produces no toxic waste and provides a faster and less aggressive way of rendering pathogens inactive.

  • Viruses in many vaccines are inactivated by means of formaldehyde.
  • Scientists at four Fraunhofer Institutes have developed a new method that makes it easier to inactivate pathogens: low-energy electron irradiation.
  • The project is funded by the Bill & Melinda Gates Foundation.
  • more info

Platform for the Identification of ncRNA-Based Diagnostics – RIBOLUTION

In molecular diagnostics the presence or concentration of specific molecules, so-called biomarkers, is used as indicators of disease or the response to a particular form of therapy. Improved early detection therefore enables difficult and costly disease progressions to be avoided.

more info

Translational medicine and pharmacology

Work undertaken by the Translational Medicine and Pharmacology project group at the Fraunhofer Institute for Molecular Biology and Applied Ecology IME is concerned with finding new drug ingredients, developing preclinical and clinical models, and clinical research.

The German Center for Lung Research

The German Center for Lung Research (DZL) is an association of the leading university and non-university institutions dedicated to lung research in Germany and including Fraunhofer ITEM.  Using translational research methods, the DZL seeks to jointly develop new approaches for the prevention, diagnosis and therapy of serious lung diseases.

more info

Clinical Research Center Hannover

The three partners to the CRC Hannover – Fraunhofer ITEM, MHH, and HZI – will be using the center collaboratively to conduct early-phase clinical trials for the development and registration of novel medications and to do patient-oriented research.